Product Pipeline and Development - AstraZeneca's product pipeline faces risks including potential delays in the delivery and launch of new medicines, which are critical for continued success[22]. - The company acknowledges that unexpected events could lead to failures in critical processes, impacting revenue and financial results[52]. - AstraZeneca has a robust development pipeline with multiple New Molecular Entities (NMEs) and significant indications under investigation, including oncology and rare diseases[111]. - The company is actively involved in research and development across various therapeutic areas, including oncology, cardiovascular, and respiratory diseases[111]. - The company is focusing on expanding its oncology portfolio with novel therapies, including combinations with PD-1/TIGIT bispecific mAb[118]. - The company anticipates significant growth in its oncology segment, with several products in late-stage development[118]. - The company is committed to advancing its research and development efforts, with a focus on innovative therapies and combination treatments[118]. - The company has multiple ongoing clinical trials for new products, including Lynparza + Imfinzi for 1st-line ovarian cancer, which is expected to launch in Q2 2023[120]. - The company anticipates the launch of several products by 2026, including Orpathys + Imfinzi for 1st-line papillary renal cell carcinoma and Wainua for transthyretin-mediated amyloid cardiomyopathy[120]. - The company is developing new therapies for rare diseases, including Koselugo for neurofibromatosis type 1, which is currently submitted for approval[120]. - The company has a robust pipeline with multiple products in various stages of development, indicating a strong future growth potential[120]. Regulatory and Compliance Risks - The company emphasizes the importance of regulatory approvals, as delays could adversely affect revenue and increase costs due to post-approval requirements[29]. - Cybersecurity and data management are critical, as failures in these areas could lead to regulatory penalties and harm the company's reputation[49]. - AstraZeneca's reliance on data as a valuable commodity necessitates compliance with an increasing range of legislative and regulatory requirements[53]. - Non-compliance with privacy and AI-related laws could lead to material regulatory sanctions, reputational damage, and loss of stakeholder trust[59]. - Changes in data-related laws may require AstraZeneca and its vendors to alter business practices, potentially leading to substantial compliance costs[60]. - AstraZeneca is under scrutiny regarding its environmental targets and performance, with increasing pressure from investors and regulators[72]. Financial Performance and Sales - Calquence (acalabrutinib) sales in the US reached $2,190 million in 2024, up from $1,815 million in 2023, representing a growth of 20.7%[122]. - Imfinzi (durvalumab) generated $2,603 million in sales in the US for 2024, compared to $2,171 million in 2023, indicating a year-over-year increase of 19.8%[122]. - Tagrisso (osimertinib) sales in the US were $2,763 million in 2024, up from $2,276 million in 2023, reflecting a growth of 21.4%[122]. - Lynparza (olaparib) reported US sales of $1,332 million in 2024, an increase from $1,254 million in 2023, marking a growth of 6.2%[122]. - Enhertu (trastuzumab deruxtecan) achieved US sales of $545 million in 2024, significantly up from $261 million in 2023, showing a growth of 108.4%[122]. - The company anticipates continued growth in the oncology segment, with multiple products expected to drive revenue through 2035[122]. - Total Oncology sales reached $20,275 million, reflecting a 21% increase year-over-year[128]. - Tagrisso generated $6,580 million in sales, up 16%, with a notable 21% growth in the US market[128]. - Farxiga sales amounted to $7,656 million, a 31% increase, with a 28% growth in the US[128]. - Total Rare Disease sales reached $8,668 million, a 14% increase, with a 12% growth in the US[128]. - Total product sales decreased by 9% to $50,938 million, with a 16% decline in the US market[128]. - The company reported a 23% increase in Immunology sales, totaling $7,416 million[128]. - Total Product Sales in 2024 were $50,938 million, indicating strong underlying demand across key therapy areas[133]. Strategic Collaborations and Acquisitions - AstraZeneca's ongoing strategic collaborations and licensing arrangements are essential for expanding its product portfolio, although they carry inherent risks[24]. - The company has made strategic acquisitions, including the purchase of Alexion in 2021, to strengthen its pipeline and expand its market presence[101][106]. - AstraZeneca recorded $1,437 million in Alliance Revenue for 2024, up from $1,022 million in 2023 and $523 million in 2022, indicating a year-over-year growth of 40.7%[126]. - The geographical review indicates a focus on expanding market presence in the US, China, and EU, with specific strategies for product launches and collaborations[127]. Market Challenges and Risks - The company faces challenges in emerging markets, including pricing affordability and competitive pressures, which could affect its business operations[32]. - AstraZeneca is heavily reliant on third-party suppliers for critical operations, and any disruptions could materially affect its reputation and financial condition[41]. - The pharmaceutical industry is experiencing pressure to limit IP protections, which could impact AstraZeneca's revenue from patented products[80]. - The company faces risks associated with data privacy, cybersecurity, and intellectual property as it increases its use of AI technologies[57]. - Changes in tax treaties or tax laws could materially adversely affect AstraZeneca's financial position and cash tax liabilities[97][98]. - AstraZeneca's patent expiry for key products is under scrutiny, with ongoing proceedings affecting revenue projections[125].

What science can do AstraZeneca Annual Report and Form 20-F Information 2024 Welcome What science can do We are a global, science-led, patient-focused pharmaceutical business, committed to excellence in the research, development and commercialisation of prescription medicines. We aim to transform the lives of patients with improved outcomes and a better quality of life. Our sustainability reporting Our sustainability reporting is prepared in line with the UK Companies Act 2006, sections 414CA and 414CB. In ...

Financial Data and Key Metrics Changes - Total revenue for 2024 increased by 21%, with a core EPS growth of 19% [3][19] - Core operating expenses rose by 14%, indicating effective cost management relative to revenue growth [3][21] - Product sales grew by 19% for the full year, driven by strong demand across regions [19] Business Line Data and Key Metrics Changes - Oncology revenues reached $22.4 billion, a 24% increase, with Tagrisso surpassing $6.5 billion in sales [34] - BioPharmaceuticals revenue grew by 21% to $21.9 billion, with respiratory and immunology products showing strong performance [56] - Rare disease revenue increased by 16% to $8.8 billion, driven by demand and new market launches [74] Market Data and Key Metrics Changes - China revenue grew by 11% overall in 2024, despite a 3% decline in Q4 due to hospital ordering dynamics [10][11] - Emerging markets saw a growth of 22%, highlighting significant unmet medical needs [12] - The inhaled market in China experienced a slowdown, with Q4 growth at 9% compared to 23% in Q3 [105] Company Strategy and Development Direction - The company aims to deliver 20 new medicines by 2030, with eight already approved [5][87] - Investments are being made in manufacturing capabilities and transformative technologies to support long-term growth [32][86] - The company is focused on achieving $80 billion in total revenue by 2030, with ongoing high-value trial readouts expected to drive growth [84][87] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential in emerging markets, particularly in China, despite current headwinds [14][108] - The company anticipates continued strong performance in 2025, with total revenue expected to increase by a high single-digit percentage [27] - Management acknowledged challenges from VBP inclusion in China but remains optimistic about overall portfolio growth [108] Other Important Information - The company is facing ongoing investigations in China related to unpaid importation taxes, with potential fines if found liable [6][10] - Significant investments are being made in next-generation manufacturing capabilities and technology to support future growth [32][30] Q&A Session Summary Question: Insights on China revenue dynamics - The revenue in Q4 declined by 3%, primarily due to hospital inventory management and a mild winter affecting respiratory product demand [10][11][102] - Management noted that the respiratory portfolio is expected to perform better as flu infections rise in early 2025 [104][108] Question: Guidance assumptions for China - The guidance for 2025 considers potential declines in China due to VBP inclusion for certain products, but overall growth is still anticipated [92][108] Question: Investigations and potential fines - The company disclosed a potential liability related to investigations, with fines possibly ranging from 1 to 5 times the amount of avoided import duties [95][96]

Full Year and Q4 2024 Results Conference call and webcast for investors and analysts 06 February 2025 Forward-looking statements This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statemen ...

9M and Q3 2024 Results Conference call and webcast for investors and analysts 12 November 2024 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, stateme ...

Financial Data and Key Metrics Changes - Total revenue grew by 21% in Q3 2024 and 19% year-to-date, with core EPS increasing by 27% to $2.08 in Q3 and 11% year-to-date [11][12][30] - Alliance revenue increased by 50% to $1.5 billion, driven by sales for Enhertu and Tezspire [23] - Net cash inflow from operating activities improved by $989 million in the first nine months [28] - Net debt increased by $3.8 billion, with a net debt-to-EBITDA ratio of 1.8 times [29] Business Line Data and Key Metrics Changes - Oncology total revenues grew 22% to $16 billion in the first nine months, with Tagrisso global revenues growing 17% [33][34] - BioPharmaceuticals delivered total revenue of $15.9 billion in the first nine months, representing growth of 20% [56] - Rare disease revenue grew 14% to $6.4 billion, with Ultomiris achieving a blockbuster quarter with 35% growth [72] Market Data and Key Metrics Changes - Emerging markets outside of China grew by 30% year-to-date, now accounting for 14% of total revenue [14] - The U.S. market contributed 43% of total revenue, with Europe at 21% and China at 13% [14] Company Strategy and Development Direction - The company announced a $3.5 billion investment in the U.S. for manufacturing and R&D, aiming to increase its market share in the U.S. [15][84] - The company is focused on expanding its oncology portfolio and has multiple high-value Phase 3 readouts expected [19][76] - The long-term goal is to achieve $80 billion in total revenue by 2030, with a mid-30s percentage operating margin by 2026 [78] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high-teens percentage growth for total revenue and core EPS for the full year [30] - The company acknowledged potential headwinds from the IRA and VBP in China but remains optimistic about overall growth momentum [86] - Management emphasized the importance of innovation and the U.S. market's role in supporting future growth [84] Other Important Information - The company is committed to its presence in China and continues to invest in R&D despite ongoing investigations [17][18] - The company is advancing its pipeline with several new medicines and indication expansions expected to drive future growth [76] Q&A Session Summary Question: U.S. election implications and investment focus - Management indicated that pharmaceuticals are typically not subject to import duties and emphasized the importance of the U.S. market for innovation and growth [81][83] Question: Confidence in the 2025 outlook - Management expressed confidence in achieving growth despite potential headwinds, citing strong momentum across the portfolio [85][86] Question: Materiality of impact from the investigation in China - Management stated it is too early to judge the impact but acknowledged that growth in China may slow next year [92][93] Question: Confidence in Dato-DXd and FDA review - Management highlighted ongoing discussions with the FDA regarding subgroup analyses and expressed confidence in the potential of Dato-DXd based on recent data [95][100]

AstraZeneca PLC (NASDAQ:AZN) Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ET Company Participants Pascal Soriot - Chief Executive Officer Susan Galbraith - EVP, Oncology R&D Thomas Powles - Professor of Genitourinary Oncology; Director, Barts Cancer Centre Sunil Verma - SVP, Global Head, Oncology Franchise Dave Fredrickson - EVP, Oncology Business Matt Hellmann - VP, Early Oncology Development Cristian Massacesi - Chief Medical Officer, Chief Development Officer Oncology Melissa Sc ...

AstraZeneca PLC (NASDAQ:AZN) Q2 2024 Earnings Conference Call July 25, 2024 6:45 AM ET Company Participants Andy Barnett - Head, IR Pascal Soriot - Executive Director & CEO Aradhana Sarin - Executive Director & CFO David Fredrickson - EVP, Oncology Business Susan Galbraith - EVP, Oncology Research and Development Ruud Dobber - EVP & President, BioPharmaceuticals Sharon Barr - EVP, BioPharmaceuticals Research and Development Marc Dunoyer - CEO, Alexion and Chief Strategy Officer, AstraZeneca Dave Fredrickson ...

AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Conference Call April 25, 2024 6:45 AM ET Company Participants Andy Barnett - Head of Investor Relations Pascal Soriot - Executive Director and Chief Executive Officer Aradhana Sarin - Executive Director and Chief Financial Officer David Fredrickson - Executive Vice President of Oncology Susan Galbraith - Executive Vice President of Oncology R&D Ruud Dobber - Executive Vice President of BioPharmaceuticals Business Unit Sharon Barr - Executive Vice President of B ...

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F X Form 40-F __ Indicate by check mark if the registrant ...